Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1978 Sep;33(3):425–429.

Identification of nephritic factor as an immunoglobulin.

D G Williams, A Bartlett, P Duffus
PMCID: PMC1537438  PMID: 104814

Abstract

C3 nephritic factor (C3NeF) activity in sera from three patients with mesangiocapillary glomerulonephritis, one of whom had partial lipodystrophy, was found on chromatography to be associated with fractions containing IgG and no other detectable proteins. Immunoadsorption of IgG from these fractions with a highly purified anti-IgG removed the C3NeF, and the IgG, eluted after combination with the anti-IgG, retained C3NeF activity. In each case the isolated IgG with C3NeF activity was found to contain more than one subclass of IgG and both kappa and lambda chains, indicating that the immunoglobulin comprising C3NeF in these patients is heterogeneous and not monoclonal. The identification of C3NeF as an immunoglobulin suggests that it may be an autoantibody against antigenic determinants of complement components present in the C3 convertase of the alternative pathway.

Full text

PDF
425

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper C. A., Bloch K. J., Rosen F. S. Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3. N Engl J Med. 1973 Mar 22;288(12):601–606. doi: 10.1056/NEJM197303222881204. [DOI] [PubMed] [Google Scholar]
  2. Avrameas S., Ternynck T. The cross-linking of proteins with glutaraldehyde and its use for the preparation of immunoadsorbents. Immunochemistry. 1969 Jan;6(1):53–66. doi: 10.1016/0019-2791(69)90178-5. [DOI] [PubMed] [Google Scholar]
  3. Charlesworth J. A., Williams D. G., Sherington E., Lachmann P. J., Peters D. K. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest. 1974 Jun;53(6):1578–1587. doi: 10.1172/JCI107708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Daha M. R., Fearon D. T., Austen K. F. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol. 1976 Jan;116(1):1–7. [PubMed] [Google Scholar]
  5. Davis A. E., 3rd, Arnaout M. A., Alper C. A., Rosen F. S. Transfer of C3 nephritic factor from mother to fetus. Is C3 nephritic factor IgG? N Engl J Med. 1977 Jul 21;297(3):144–145. doi: 10.1056/NEJM197707212970306. [DOI] [PubMed] [Google Scholar]
  6. Davis A. E., 3rd, Ziegler J. B., Gelfand E. W., Rosen F. S., Alper C. A. Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3980–3983. doi: 10.1073/pnas.74.9.3980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Henson P. M. Immunoconglutinins of different immunoglobulin classes demonstrated by the antiglobulin reaction. Immunology. 1968 May;14(5):697–705. [PMC free article] [PubMed] [Google Scholar]
  8. Karstorp A. C3 activator and hypocomplementaemia in a "healthy" woman. Br Med J. 1976 Feb 28;1(6008):501–502. doi: 10.1136/bmj.1.6008.501-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Peters D. K., Charlesworth J. A., Sissons J. G., Williams D. G., Boulton-Jones J. M., Evans D. J., Kourilsky O., Morel-Maroger L. Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia. Lancet. 1973 Sep 8;2(7828):535–538. doi: 10.1016/s0140-6736(73)92351-9. [DOI] [PubMed] [Google Scholar]
  10. Peters D. K., Lachmann P. J. Immunity deficiency in pathogenesis of glomerulonephritis. Lancet. 1974 Jan 12;1(7846):58–60. doi: 10.1016/s0140-6736(74)93056-6. [DOI] [PubMed] [Google Scholar]
  11. Peters D. K., Martin A., Weinstein A., Cameron J. S., Barratt T. M., Ogg C. S., Lachmann P. J. Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol. 1972 Jul;11(3):311–320. [PMC free article] [PubMed] [Google Scholar]
  12. Sissons J. G., West R. J., Fallows J., Williams D. G., Boucher B. J., Amos N., Peters D. K. The complement abnormalities of lipodystrophy. N Engl J Med. 1976 Feb 26;294(9):461–465. doi: 10.1056/NEJM197602262940902. [DOI] [PubMed] [Google Scholar]
  13. Spitzer R. E., Vallota E. H., Forristal J., Sudora E., Stitzel A., Davis N. C., West C. D. Serum C'3 lytic system in patients with glomerulonephritis. Science. 1969 Apr 25;164(3878):436–437. doi: 10.1126/science.164.3878.436. [DOI] [PubMed] [Google Scholar]
  14. Thompson R. A. C3 inactivating factor in the serum of a patient with chronic hypocomplementaemic proliferative glomerulo-nephritis. Immunology. 1972 Jan;22(1):147–158. [PMC free article] [PubMed] [Google Scholar]
  15. Thompson R. A., Lachmann P. J. Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med. 1970 Apr 1;131(4):629–641. doi: 10.1084/jem.131.4.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Thompson R. A., White R. H. Partial lipodystrophy and hypocomplementaemic nephritis. Lancet. 1973 Sep 22;2(7830):679–679. doi: 10.1016/s0140-6736(73)92516-6. [DOI] [PubMed] [Google Scholar]
  17. Vallota E. H., Götze O., Spiegelberg H. L., Forristal J., West C. D., Müller-Eberhard H. J. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement. J Exp Med. 1974 May 1;139(5):1249–1261. doi: 10.1084/jem.139.5.1249. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES